This was from a 2012 article..... Rosiglitazo
Post# of 30028
Rosiglitazone--It was originally developed as a diabetes medication that increases a cell's sensitivity to insulin. Researchers predicted a potential treatment for Alzheimer's due to links between the disease and Type II diabetes and pushed the drug into clinical trials, but it failed to provide any cognitive improvement.
Not to be forgotten for its efforts, Roche's ($RHHBY) Genentech is now taking crenezumab in a different direction. Only mildly positive early clinical data for the antibody, along with news of failures from drugs with more positive early data, persuaded the Swiss pharma giant to switch focus from treatment to prevention. The company, in partnership with the Alzheimer's Association, is currently preparing for its first study of cognitively healthy individuals. The Big Pharma spotlight moves away from high-risk potential blockbusters to finding preventative measures for at-risk populations.
Keep your eye on the prize.....